Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates... see more

Recent & Breaking News (NDAQ:INCY)

Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018

PR Newswire August 30, 2017

Technical Snapshots for These Biotech Stocks -- ImmunoGen, Incyte, Infinity Pharma, and Jazz Pharma

PR Newswire August 11, 2017

Investor Network: Incyte Corporation to Host Earnings Call

Accesswire August 1, 2017

Incyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs

Business Wire August 1, 2017

Lilly and Incyte Provide Update on Baricitinib

PR Newswire July 25, 2017

Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Acute Graft-Versus-Host Disease

Business Wire July 20, 2017

Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results

GlobeNewswire July 11, 2017

Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis

PR Newswire July 3, 2017

New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017

PR Newswire June 16, 2017

Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017)

PR Newswire June 13, 2017

This Biotech Name Could Be Best In Breed For 2017

Benzinga.com  June 13, 2017

Incyte to Present at Upcoming Investor Conferences

Business Wire June 7, 2017

Les données provenant de l'essai clinique portant sur la combinaison d'Epacadostat et d' Opdivo® (nivolumab) démontrent des réponses cliniques durables chez les patients atteints d'un mélanome et d'un cancer...

Business Wire June 7, 2017

Incyte Analyst and Investor Event to Highlight Clinical Data Presentations from ASCO 2017

Business Wire June 5, 2017

Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer

Business Wire June 5, 2017

Updated Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (Pembrolizumab) Demonstrate Clinical Activity across Multiple Tumor Types

Business Wire June 5, 2017

Une combinaison d'epacadostat et de Keytruda® (pembrolizumab) fait état d'une activité dans un essai clinique pour les patients atteints de cancer du poumon non à petites cellules avancé (CPNPC)

Business Wire June 3, 2017

Combination of Incyte’s Epacadostat plus Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Business Wire June 3, 2017

Incyte to Present at Upcoming Investor Conferences

Business Wire May 22, 2017

The Most Notable Abstracts Released Ahead Of ASCO 2017

Benzinga.com  May 19, 2017